Henry Schein (HSIC) Q1 2026 Earnings Transcript

Henry Schein reported Q1 2026 sales of $3.4 billion, up 6.3%, with non-GAAP operating margin expanding 28 bps to 7.53% and adjusted EBITDA rising 11.6% to $289 million. Management kept full-year guidance unchanged at 3%-5% sales growth and $5.23-$5.37 non-GAAP EPS, while highlighting $125 million of share repurchases, a $11 million remeasurement gain from the S.I.N. 360 deal, and ongoing restructuring efforts targeting a $125 million run-rate benefit by year-end. Results were supported by strong dental and technology growth, partly offset by softer medical test demand tied to a light flu season.

Analysis

HSIC’s setup is less about near-term volume and more about mix-driven compounding: the market is still underestimating how much software, e-commerce, and value implants can dilute the lower-quality distribution mix over the next 6-12 months. The key second-order effect is that every incremental share gain in DSO/dental workflows increases wallet penetration into equipment, consumables, and SaaS, which should widen lifetime value per customer even if top-line growth looks only mid-single digit.

The re-rating risk is that investors may anchor on the headline distribution growth and miss that management is effectively converting HSIC from a pure distributor into a partially recurring operating platform. If the AI workflow launch and Henry Schein One monetization convert even a modest fraction of the 13k+ subscriber base into broader software/e-services attach, the margin profile can improve faster than consensus expects, especially once the U.S. e-commerce migration completes and back-office cost actions begin flowing in 2H26.

Near term, the main overhang is that reported margins and cash flow are still being distorted by seasonal working capital, restructuring, and transaction accounting, which can keep the stock cheap longer than fundamentals justify. The bigger risk is execution: if premium implants remain soft and price competition intensifies in digital equipment, investors could lose patience before the value-creation program becomes visible in quarterly EPS. That said, the guidance framework appears conservative on the back half if cost actions and mix hold, making any short-term pullback on macro/oil noise a buyable event rather than a thesis break.

Contrarian view: the consensus is likely too focused on whether this is a low-growth distributor and too little on the optionality embedded in its customer-control layer. The right frame is not a 3-5% sales grower, but a company with improving monetization density per practice, which is far more valuable if software/AI and e-commerce become the front door to the rest of the basket.

Key Decisions for Investors

• Long HSIC on any 3%-5% pullback over the next 2-4 weeks; target a 10%-15% upside re-rating over 6-9 months as 2H26 margin actions become visible.
• Buy HSIC Jan-2027 call spreads to express the view that operating leverage, not just revenue growth, drives EPS re-acceleration; downside is limited to premium, upside comes from multiple expansion if margins hold above expectations.
• Pair trade: long HSIC / short a lower-quality dental distributor or broad healthcare distributor basket for 6-12 months, betting on better mix, software attach, and pricing power.
• If HSIC sells off on oil/freight headlines without evidence of demand deterioration, add to the long; management has room to offset costs via pricing and mix before volumes are threatened.
• Avoid chasing after a strong earnings reaction; wait for a post-call digestion period, since the stock likely needs proof points from the August e-commerce rollout and 2H26 savings to sustain a move.